Alternative Investment Management
New York City, New Yorkaim13.com
Overview
An independent, privately-held, and owner-operated investment management firm that partners with individuals, family offices, foundations, endowments, and pension plans. The firm's roots trace back to 1999 and it specializes in selective, integrated exposure to various investment strategies, including private equity, hedge funds, and direct investments in dual-use technologies.
Portfolio Companies
11
Website
aim13.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Ansa Biotechnologies | Oct 2025 | Series B | Co-investor |
| Fortem Technologies | Feb 2023 | Series B | Lead |
| Fortem Technologies | Feb 2023 | Series B | - |
| Allied BioScience | Apr 2020 | Series B Extension | Co-investor |
| SRFC Bio, Inc. | Apr 2020 | Series B Extension | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
